Zobrazeno 1 - 10
of 2 357
pro vyhledávání: '"Treat to target"'
Glucocorticoids remain the basis for treatment of myasthenia gravis in the era of targeted therapies
Autor:
LI Hai-feng
Publikováno v:
Chinese Journal of Contemporary Neurology and Neurosurgery, Vol 24, Iss 5, Pp 295-307 (2024)
Myasthenia gravis (MG) treatment has entered an era of targeted therapies. Different targeted therapies take effect in various aspects of pathogenic mechanisms in MG. For a steady long-term control of MG symptoms, immunotherapies that reduce the prod
Externí odkaz:
https://doaj.org/article/2267dafdba7c4616b870b530864be82c
Autor:
Bastiaan T. van Dijk, Sytske Anne Bergstra, J. Merlijn van den Berg, Dieneke Schonenberg-Meinema, Lisette W.A. van Suijlekom-Smit, Marion A.J. van Rossum, Yvonne Koopman-Keemink, Rebecca ten Cate, Cornelia F. Allaart, Daniëlle M.C. Brinkman, Petra C.E. Hissink Muller
Publikováno v:
Pediatric Rheumatology Online Journal, Vol 22, Iss 1, Pp 1-9 (2024)
Abstract Background Etanercept has been studied in doses up to 0.8 mg/kg/week (max 50 mg/week) in juvenile idiopathic arthritis (JIA) patients. In clinical practice higher doses are used off-label, but evidence regarding the relation with outcomes is
Externí odkaz:
https://doaj.org/article/fa8d9324980a49eb9888c4d773ba6e32
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
ObjectiveTo collect real-world data regarding the attainment of the early-achieved lupus low disease activity state (LLDAS) in systemic lupus erythematosus (SLE) patients receiving telitacicept or belimumab treatment, and identify factors predictive
Externí odkaz:
https://doaj.org/article/9d0386e627774389bff14c672884dee8
Autor:
Xi Xi Yu, Jia Deng, Qiu Xia Chen, Shi Yuan Qiu, Chao Hui Jiang, Yi Qian Wu, Qin Yang, Gao Fu Zhang, Hai Ping Yang, Fei Zhao, Qiu Li, Ai Hua Zhang, Mo Wang
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundThis study aims to explore the clinical value of low disease activity state (LDAS) in the treat-to-target strategy of pediatric systemic lupus erythematosus (pSLE) and find the risk factors for never reaching LDAS.MethodsA total of 272 chil
Externí odkaz:
https://doaj.org/article/5b941eea042f4ac8b496d3b1cd3a804e
Autor:
Shawn G. Kwatra, Marjolein de Bruin-Weller, Jonathan I. Silverberg, Peter Lio, Mette Deleuran, Handan Aydin, Brian M. Calimlim, Michael C. Lane, Yingyi Liu, Sarah Ofori, Stephan Weidinger
Publikováno v:
Acta Dermato-Venereologica, Vol 104 (2024)
A treat-to-target approach was recently developed to guide systemic treatment for adults with atopic dermatitis (AD). Recommendations outlined criteria for a 3-month initial acceptable treatment target and a 6-month optimal target, evaluated using gl
Externí odkaz:
https://doaj.org/article/f3b4e95ef131423ba2e4036632fc38b1
Autor:
Y El Miedany, M El Gaafary, M Toth, A Abdel Azim, D Palmer, G Dolbear, D Affam, W Hassan, SA Tabra, S Saber, MH Abu-zaid
Publikováno v:
Egyptian Rheumatology and Rehabilitation, Vol 51, Iss 1, Pp 1-17 (2024)
Abstract Background The aim of this work is to develop guidelines for health care professionals in the giant cell arteritis diagnosis and management, based on patients’ stratification and targeted outcome measures. Results Fourteen expert panel had
Externí odkaz:
https://doaj.org/article/7170df546dba47729a1014a10e80d485
Publikováno v:
Clinical and Research Journal in Internal Medicine, Vol 4, Iss 2, Pp 457-463 (2023)
Background: Rheumatoid arthritis (RA) is the most frequent type of systemic inflammatory arthritis. Aim: to observe RA patients' clinical characteristics in Malang and assess the adherence of the clinical data to the existing guideline for the tre
Externí odkaz:
https://doaj.org/article/e27ddcebd59741f3bce4fb8bc829a09a
Publikováno v:
Global Rheumatology, Vol 5 (2024)
Introduction: Certolizumab pegol (CTZ) is a tumor necrosis factor-alpha (TNF-α) inhibitor biological agent that has demonstrated efficacy in controlling rheumatoid arthritis (RA). Identifying predictive factors for treatment success and assessing it
Externí odkaz:
https://doaj.org/article/b305c80268e448d7bebf1f4a89ee17f6
Autor:
Agner R. Parra Sánchez, Ronald F. van Vollenhoven, Eric F. Morand, Ian N. Bruce, Rangi Kandane-Rathnayake, Gudrun Weiss, Raj Tummala, Hussein Al-Mossawi, Alessandro Sorrentino
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 6, Pp 1459-1477 (2023)
Abstract Remission is the established therapeutic goal for patients with systemic lupus erythematosus (SLE) and is currently defined by the widely adopted Definition Of Remission In SLE (DORIS) criteria. Attainment of remission is rare in the clinica
Externí odkaz:
https://doaj.org/article/e1fcf1e203f84ba88cc0a6c10e3a1017
Autor:
Louis Bessette, Boulos Haraoui, Emmanouil Rampakakis, Joanna Dembowy, Marc-Olivier Trépanier, Janet Pope
Publikováno v:
Arthritis Research & Therapy, Vol 25, Iss 1, Pp 1-13 (2023)
Abstract Background To compare a treat-to-target (T2T) approach and routine care (RC) in adults with active to severely active rheumatoid arthritis (RA) initiating subcutaneous abatacept. Methods A 12-month cluster-randomized trial in active RA patie
Externí odkaz:
https://doaj.org/article/5012c58ad7594116a451188357184c8a